Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193089
Status:
COMPLETED
Last Update Posted:
2015-12-10
First Post:
2005-09-12
Brief Title:
Docetaxel Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of Weekly Docetaxel Vinorelbine and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase II trial we attempt to improve upon the efficacy of the trastuzumabvinorelbine combination by adding weekly docetaxel When administered on a weekly schedule docetaxel is well tolerated with minimal myelosuppression so that it is likely that fully efficacious doses of all three drugs can be administered
Detailed Description:
Upon determination of eligibility all patients will be receive
Trastuzumab Vinorelbine Docetaxel
Trastuzumab Vinorelbine Docetaxel
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H2369n | None | None | None |
| GIA 11180 | None | None | None |